A5295: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects
Study Status
Open to Enrollment
Study Description
This study is for HIV-negative and HIV-positive men and women who are suspected of having pulmonary TB who are undergoing sputum evaluation for pulmonary TB.
This study is evaluating the Xpert MTB/RIF assay, which is a new faster test to diagnose TB and to test for rifampin resistance. The study will see if Xpert MTB/RIF is as accurate as or even more accurate than the current tests. Participants will not receive any TB treatment through this study.
For the convenience of our study participants, we have 2 locations:
Upper East Side/East 68th Street: Baker 24 at NewYork-Presbyterian/Weill Cornell Medical Center
Sponsor
ACTG
Key Eligibility
- Men and women age 18 and older
- HIV-positive or HIV-negative
- Suspected pulmonary TB
- Detailed eligibility reviewed when you contact the study team
Principal Investigator
Contact
- Todd Stroberg, RN (Chelsea Clinic)
- (212) 746-7198
- [email protected]
- Valery Hughes, FNP (East 68th Street Clinic)
- (212) 746-4393
- [email protected]
Protocol ID
A5295
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]